Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells

Feng Min Lin, Li Ru Chen, En Hau Lin, Ferng Chun Ke, Hsin Yi Chen, Meng Jen Tsai, Pei Wen Hsiao

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Chronic inflammation can augment tumor development in various types of cancers, including prostate cancer (PCa). Reduction of inflammation is therefore an important anticancer therapeutic opportunity. Here, we report four anti-proliferative phytocompounds in Wedelia chinensis, an oriental herbal medicine, identified through their ability to modulate the androgen receptor (AR) activation of transcription from prostate-specific antigen promoter in PCa cells. The 50% inhibition concentration values of indole-3-carboxylaldehyde, wedelolactone, luteolin and apigenin, were 34.9, 0.2, 2.4 and 9.8 μM, respectively. A formula that combined the phytocompounds in the same proportions as in the herbal extract decreased the dosage of each compound required to achieve maximal AR inhibition. In correlation with the AR suppression effect, these active compounds specifically inhibited the growth of AR-dependent PCa cells and as a combination formula they also synergistically suppressed growth in AR-dependent PCa cells. Our study has identified synergistic effects of active compounds in W. chinensis and demonstrated their potential in PCa prevention and therapy. The paradigm of multiple activities and synergism is a useful framework to investigate the therapeutic effects of whole extracts from assorted medicinal plant species.

Original languageEnglish
Pages (from-to)2521-2529
Number of pages9
JournalCarcinogenesis
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Wedelia
Androgens
Androgen Receptors
Prostatic Neoplasms
Growth
East Asian Traditional Medicine
Inflammation
Apigenin
Luteolin
Herbal Medicine
Therapeutic Uses
Prostate-Specific Antigen
Medicinal Plants
Transcriptional Activation

ASJC Scopus subject areas

  • Cancer Research

Cite this

Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. / Lin, Feng Min; Chen, Li Ru; Lin, En Hau; Ke, Ferng Chun; Chen, Hsin Yi; Tsai, Meng Jen; Hsiao, Pei Wen.

In: Carcinogenesis, Vol. 28, No. 12, 12.2007, p. 2521-2529.

Research output: Contribution to journalArticle

Lin, Feng Min ; Chen, Li Ru ; Lin, En Hau ; Ke, Ferng Chun ; Chen, Hsin Yi ; Tsai, Meng Jen ; Hsiao, Pei Wen. / Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. In: Carcinogenesis. 2007 ; Vol. 28, No. 12. pp. 2521-2529.
@article{ab355aaef26f49789f3fee925e564b82,
title = "Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells",
abstract = "Chronic inflammation can augment tumor development in various types of cancers, including prostate cancer (PCa). Reduction of inflammation is therefore an important anticancer therapeutic opportunity. Here, we report four anti-proliferative phytocompounds in Wedelia chinensis, an oriental herbal medicine, identified through their ability to modulate the androgen receptor (AR) activation of transcription from prostate-specific antigen promoter in PCa cells. The 50{\%} inhibition concentration values of indole-3-carboxylaldehyde, wedelolactone, luteolin and apigenin, were 34.9, 0.2, 2.4 and 9.8 μM, respectively. A formula that combined the phytocompounds in the same proportions as in the herbal extract decreased the dosage of each compound required to achieve maximal AR inhibition. In correlation with the AR suppression effect, these active compounds specifically inhibited the growth of AR-dependent PCa cells and as a combination formula they also synergistically suppressed growth in AR-dependent PCa cells. Our study has identified synergistic effects of active compounds in W. chinensis and demonstrated their potential in PCa prevention and therapy. The paradigm of multiple activities and synergism is a useful framework to investigate the therapeutic effects of whole extracts from assorted medicinal plant species.",
author = "Lin, {Feng Min} and Chen, {Li Ru} and Lin, {En Hau} and Ke, {Ferng Chun} and Chen, {Hsin Yi} and Tsai, {Meng Jen} and Hsiao, {Pei Wen}",
year = "2007",
month = "12",
doi = "10.1093/carcin/bgm137",
language = "English",
volume = "28",
pages = "2521--2529",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells

AU - Lin, Feng Min

AU - Chen, Li Ru

AU - Lin, En Hau

AU - Ke, Ferng Chun

AU - Chen, Hsin Yi

AU - Tsai, Meng Jen

AU - Hsiao, Pei Wen

PY - 2007/12

Y1 - 2007/12

N2 - Chronic inflammation can augment tumor development in various types of cancers, including prostate cancer (PCa). Reduction of inflammation is therefore an important anticancer therapeutic opportunity. Here, we report four anti-proliferative phytocompounds in Wedelia chinensis, an oriental herbal medicine, identified through their ability to modulate the androgen receptor (AR) activation of transcription from prostate-specific antigen promoter in PCa cells. The 50% inhibition concentration values of indole-3-carboxylaldehyde, wedelolactone, luteolin and apigenin, were 34.9, 0.2, 2.4 and 9.8 μM, respectively. A formula that combined the phytocompounds in the same proportions as in the herbal extract decreased the dosage of each compound required to achieve maximal AR inhibition. In correlation with the AR suppression effect, these active compounds specifically inhibited the growth of AR-dependent PCa cells and as a combination formula they also synergistically suppressed growth in AR-dependent PCa cells. Our study has identified synergistic effects of active compounds in W. chinensis and demonstrated their potential in PCa prevention and therapy. The paradigm of multiple activities and synergism is a useful framework to investigate the therapeutic effects of whole extracts from assorted medicinal plant species.

AB - Chronic inflammation can augment tumor development in various types of cancers, including prostate cancer (PCa). Reduction of inflammation is therefore an important anticancer therapeutic opportunity. Here, we report four anti-proliferative phytocompounds in Wedelia chinensis, an oriental herbal medicine, identified through their ability to modulate the androgen receptor (AR) activation of transcription from prostate-specific antigen promoter in PCa cells. The 50% inhibition concentration values of indole-3-carboxylaldehyde, wedelolactone, luteolin and apigenin, were 34.9, 0.2, 2.4 and 9.8 μM, respectively. A formula that combined the phytocompounds in the same proportions as in the herbal extract decreased the dosage of each compound required to achieve maximal AR inhibition. In correlation with the AR suppression effect, these active compounds specifically inhibited the growth of AR-dependent PCa cells and as a combination formula they also synergistically suppressed growth in AR-dependent PCa cells. Our study has identified synergistic effects of active compounds in W. chinensis and demonstrated their potential in PCa prevention and therapy. The paradigm of multiple activities and synergism is a useful framework to investigate the therapeutic effects of whole extracts from assorted medicinal plant species.

UR - http://www.scopus.com/inward/record.url?scp=36949025979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949025979&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgm137

DO - 10.1093/carcin/bgm137

M3 - Article

C2 - 17942463

AN - SCOPUS:36949025979

VL - 28

SP - 2521

EP - 2529

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 12

ER -